(Reuters) - The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. Merck's Ragwitek will compete with Stallergenes SA's immunotherapy treatment for five types of grass pollen, which was approved by the FDA earlier this month.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment